MX2020013853A - Compuestos innovadores. - Google Patents

Compuestos innovadores.

Info

Publication number
MX2020013853A
MX2020013853A MX2020013853A MX2020013853A MX2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A
Authority
MX
Mexico
Prior art keywords
compounds
novel compounds
compositions
combinations
antitrypsin
Prior art date
Application number
MX2020013853A
Other languages
English (en)
Inventor
John Liddle
Kate Smith
Alexis Denis
Nerina Dodic
David Lomas
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810290.5A external-priority patent/GB201810290D0/en
Priority claimed from GBGB1906708.1A external-priority patent/GB201906708D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2020013853A publication Critical patent/MX2020013853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones, combinaciones y medicamentos que contienen dichos compuestos y procesos para su preparación. La invención también se refiere al uso de dichos compuestos, combinaciones, composiciones y medicamentos, por ejemplo, como moduladores de alfa 1 antitripsina y para el tratamiento de enfermedades asociadas con alfa antitripsina, particularmente enfermedades del hígado.
MX2020013853A 2018-06-22 2019-06-21 Compuestos innovadores. MX2020013853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810290.5A GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds
GBGB1906708.1A GB201906708D0 (en) 2019-05-13 2019-05-13 Novel compounds
PCT/GB2019/051761 WO2019243841A1 (en) 2018-06-22 2019-06-21 Novel compounds

Publications (1)

Publication Number Publication Date
MX2020013853A true MX2020013853A (es) 2021-05-27

Family

ID=67139769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013853A MX2020013853A (es) 2018-06-22 2019-06-21 Compuestos innovadores.

Country Status (10)

Country Link
US (2) US20210276952A1 (es)
EP (1) EP3810131A1 (es)
CN (1) CN113286586A (es)
AU (1) AU2019289228A1 (es)
BR (1) BR112020026314A2 (es)
CA (1) CA3103920A1 (es)
IL (1) IL279526A (es)
MX (1) MX2020013853A (es)
SG (1) SG11202012765PA (es)
WO (1) WO2019243841A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918413D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
JP2023520400A (ja) * 2020-04-03 2023-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ－１－アンチトリプシン欠損症（ａａｔｄ）を治療するためのアルファ－１－アンチトリプシンモジュレーターとしてのインドール誘導体
AU2021247285A1 (en) * 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
BR112022019794A2 (pt) * 2020-04-03 2022-12-06 Vertex Pharma Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)
WO2021203028A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
CA3178470A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency
CN113801053B (zh) * 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
CA2156408C (en) 1993-03-17 2005-02-15 Daniel C. Duan Aerosol formulation containing a polyester dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US9801637B2 (en) 2006-03-13 2017-10-31 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
KR101402702B1 (ko) 2011-09-15 2014-06-05 (주)알테오젠 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
CN107849084B (zh) * 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
CN113801053B (zh) 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法

Also Published As

Publication number Publication date
CN113286586A (zh) 2021-08-20
CA3103920A1 (en) 2019-12-26
WO2019243841A1 (en) 2019-12-26
US20210276952A1 (en) 2021-09-09
AU2019289228A1 (en) 2021-01-21
BR112020026314A2 (pt) 2021-03-30
EP3810131A1 (en) 2021-04-28
US11919856B2 (en) 2024-03-05
SG11202012765PA (en) 2021-01-28
IL279526A (en) 2021-01-31
US20220340525A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2020013853A (es) Compuestos innovadores.
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
DOP2018000240A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
PH12017501921A1 (en) Novel compounds
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
BR112016028255A2 (pt) agentes imunorreguladores
CR20210201A (es) Nuevos compuestos antihelmínticos
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12021550872A1 (en) Therapeutic compounds
MX2019013419A (es) Compuestos plaguicidas biciclicos.
EA202090448A1 (ru) Дигидрооксадиазиноны
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
NZ760781A (en) Process for the preparation of standardized composition of arjunoglucoside from the bark of terminalia arjuna
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento